SARS-CoV-2

SARS-CoV-2 is a positive-sense single-stranded RNA virus. It is contagious in humans and is the cause of the coronavirus disease 2019 (COVID-19).

Featured

News & Views | 12 July 2022

Omicron: a shift in the biology of SARS-CoV-2

Nature Microbiology 7, 1114-1115

Latest Research and Reviews

Research | 09 August 2022

The mechanism of RNA capping by SARS-CoV-2
- Gina J. Park
- , Adam Osinski
- & Vincent S. Tagliabracci
Nature, 1
Research
08 August 2022 | Open Access

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

Whilst the ChAdOx1 nCoV-19 (AZD1222) vaccine has demonstrated efficacy against symptomatic disease, variants of concern (VOCs) with spike protein substitutions have led researchers to explore updating vaccines from ancestral spike protein. Authors use a Syrian hamster model to evaluate a vaccine encoding the spike protein of Beta VOC and assess efficacy against VOCs.
- Neeltje van Doremalen
- , Jonathan E. Schulz
- & Vincent J. Munster
Nature Communications 13, 4610
Research
08 August 2022 | Open Access

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Here the authors show that a third SARS-CoV-2 vaccination significantly boosts neutralizing antibodies against Omicron subvariants and that hybrid immunity (infection and vaccination) results in broader neutralization activity and cross-reactive antibody affinity maturation.
- Lorenza Bellusci
- , Gabrielle Grubbs
- & Surender Khurana
Nature Communications 13, 4617
Research
08 August 2022 | Open Access

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

Responses to SARS-CoV-2 vaccines in different populations are important to define efficacy. Here the authors show using a cohort in Singapore that two doses of mRNA vaccine is less effective in recipients over 60 years of age and that a further dose of vaccine can improve these antibody levels.
- Laurent Renia
- , Yun Shan Goh
- & Lisa F. P. Ng
Nature Communications 13, 4615
Research | 08 August 2022

DOCK2 is involved in the host genetics and biology of severe COVID-19
- Ho Namkoong
- , Ryuya Edahiro
- & Yukinori Okada
Nature, 1-6
Research
08 August 2022 | Open Access

COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation

Vaccines induce beneficial immunity for COVID-19, but immune waning prompts boosting vaccination. Here, the authors show that a third, boosting dose of COVID-19 mRNA vaccine induces transient CD8 + T effector cell response while conserving the CD8 memory T cell pool, thereby permitting reactivation of spike-specific CD8 + T cells upon breakthrough infection or 4th vaccination.
- Matthias Reinscheid
- , Hendrik Luxenburger
- & Maike Hofmann
Nature Communications 13, 4631

All Research & Reviews

News and Comment

Editorial | 03 August 2022

Get childhood immunizations back on track after COVID

The effects of the pandemic mean childhood vaccination rates are the lowest for a generation. There is a risk of preventable diseases resurging unless governments treat this as a priority.

Nature 608, 7-8
News | 03 August 2022

Mild-COVID drugs, Omicron protection and disco-ball satellite

The latest science news, in brief.

Nature 608, 13
News | 02 August 2022

Heart disease after COVID: what the data say

Some studies suggest that the risk of cardiovascular problems, such as a heart attack or stroke, remains high even many months after a SARS-CoV-2 infection clears up. Researchers are starting to pin down the frequency of these issues and what is causing the damage.
- Saima May Sidik
Nature 608, 26-28
Research Highlights | 01 August 2022

SARS-CoV-2 tunnels to new cells

A study in cell lines suggests that SARS-CoV-2 potentially spreads through tunnelling nanotubes.
- Ursula Hofer
Nature Reviews Microbiology, 1
News | 29 July 2022

Coronapod: the open-science plan to unseat big Pharma and tackle vaccine inequity

Can a collaboration of 15 countries, co-led by the WHO, deliver vaccine independence to the global south against all the odds?
- Noah Baker
- & Amy Maxmen
Nature
Comments & Opinion | 27 July 2022

Encouraging vaccine uptake: lessons from behavioural science

Established models of behavioural science can help to explain the suboptimal COVID-19 vaccine uptake even in countries with a plentiful supply, showing that increasing vaccination is not just about increasing knowledge and motivation, but also about increasing the opportunity for vaccination.
- Susan Michie
Nature Reviews Immunology, 1-2

All News & Comment

SARS-CoV-2

Featured

Omicron: a shift in the biology of SARS-CoV-2

Latest Research and Reviews

The mechanism of RNA capping by SARS-CoV-2

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

DOCK2 is involved in the host genetics and biology of severe COVID-19

COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation

News and Comment

Get childhood immunizations back on track after COVID

Mild-COVID drugs, Omicron protection and disco-ball satellite

Heart disease after COVID: what the data say

SARS-CoV-2 tunnels to new cells

Coronapod: the open-science plan to unseat big Pharma and tackle vaccine inequity

Encouraging vaccine uptake: lessons from behavioural science

Quick links

Discover content

Publishing policies

Author & Researcher services

Libraries & institutions

Advertising & partnerships

Career development

Regional websites

Legal & Privacy

SARS-CoV-2

Featured

Latest Research and Reviews

News and Comment

Search

Quick links